Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer

Breast Cancer Research

Volumn 14, Issue 4, 2012, Pages

  Cortez, Valerie ^a,b   Mann, Monica ^a,b   Tekmal, Seshidhar ^a   Suzuki, Takayoshi ^c,d   Miyata, Naoki ^e   Rodriguez Aguayo, Cristian ^f   Lopez Berestein, Gabriel ^f   Sood, Anil K ^f   Vadlamudi, Ratna K ^a,g  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e NAGOYA CITY UNIVERSITY   (Japan)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; BENZAMIDE DERIVATIVE; ESTROGEN RECEPTOR ALPHA; HISTONE DEMETHYLASE; HISTONE H3; KI 67 ANTIGEN; LETROZOLE; LIPOSOME; N 3 [[3 (2 AMINOCYCLOPROPYL)PHENOXY] 1 (BENZYLCARBAMOYL)PROPYL]BENZAMIDE; PARGYLINE; PHOSPHATIDYLCHOLINE; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; PROTEIN; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; 2-(3-(3-BENZAMIDO-4-(BENZYLAMINO)-4-OXOBUTOXY)PHENYL)CYCLOPROPYLAMINE; CARCINOGEN; COREPRESSOR PROTEIN; CYCLOPROPANE DERIVATIVE; ESTROGEN; HISTONE; KDM1A PROTEIN, HUMAN; PELP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RESISTANCE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; ESTROGEN SYNTHESIS; FEMALE; GENETIC MARKER; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE; POSTMENOPAUSE; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; BREAST NEOPLASMS; CARCINOGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CO-REPRESSOR PROTEINS; CYCLOPROPANES; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESTROGENS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONE DEMETHYLASES; HISTONES; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PARGYLINE; TRANSCRIPTION FACTORS;

EID: 84864913725     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3229     Document Type: Article

References (48)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK, . (eds) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. 2011, Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site, (eds)., http://seer.cancer.gov/csr/1975_2008/
2. Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis 2005, 24:93-105.
3. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?. Br J Cancer 2006, 18:661-666.
4. Utsumi T, Kobayashi N, Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 2007, 14:194-199. 10.2325/jbcs.959, 17485906.
5. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644. 10.1126/science.1071884, 12040178.
6. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999, 20:321-344. 10.1210/er.20.3.321, 10368774.
7. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007, 28:575-587. 10.1210/er.2007-0012, 17609497.
8. Lydon JP, O'Malley BW. Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology 2011, 152:19-25. 10.1210/en.2010-1012, 3219052, 21047941.
9. Vadlamudi RK, Manavathi B, Balasenthil S, Nair SS, Yang Z, Sahin AA, Kumar R. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res 2005, 65:7724-7732. 1343458, 16140940.
10. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Pogribny IP. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007, 6:2010-2018. 10.4161/cc.6.16.4549, 17700064.
11. Litt MD, Simpson M, Gaszner M, Allis CD, Felsenfeld G. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science 2001, 293:2453-2455. 10.1126/science.1064413, 11498546.
12. Noma K, Allis CD, Grewal SI. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 2001, 293:1150-1155. 10.1126/science.1064150, 11498594.
13. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008, 319:202-206. 10.1126/science.1147674, 18187655.
14. Rajhans R, Nair HB, Nair SS, Cortez V, Ikuko K, Kirma NB, Zhou D, Holden AE, Brann DW, Chen S, Tekmal RR, Vadlamudi RK. Modulation of in situ estrogen synthesis by PELP1: potential ER autocrine signaling loop in breast cancer cells. Mol Endocrinol 2008, 22:649-664. 2262166, 18079323.
15. Vadlamudi RK, Kumar R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal 2007, 5:e004. 1876599, 17525794.
16. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK. Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res 2007, 67:5505-5512. 10.1158/0008-5472.CAN-06-3647, 2774841, 17545633.
17. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, Ellis IO. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 2009, 120:603-612.
18. Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schule R, Brann DW, Tekmal RR, Vadlamudi RK. PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 2010, 11:438-444. 10.1038/embor.2010.62, 2892318, 20448663.
19. Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR, Vadlamudi RK. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat 2010, 130:377-385.
20. Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 2005, 24:3166-3176. 10.1038/sj.onc.1208502, 15735693.
21. Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer 2008, 112:679-688. 10.1002/cncr.23191, 18072255.
22. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009, 131:17536-17537. 10.1021/ja907055q, 19950987.
23. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918. 10.1158/0008-5472.CAN-05-0530, 16061675.
24. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009, 15:3770-3780. 10.1158/1078-0432.CCR-08-2306, 2752981, 19470734.
25. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004, 96:456-465. 10.1093/jnci/djh076, 15026471.
26. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res 2011, 17:2250-2259. 10.1158/1078-0432.CCR-10-2718, 21421858.
27. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006, 12:4916-4924. 10.1158/1078-0432.CCR-06-0021, 3144499, 16914580.
28. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006, 5:1708-1713. 10.4161/cbt.5.12.3468, 17106249.
29. Lan F, Nottke AC, Shi Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 2008, 20:316-325. 10.1016/j.ceb.2008.03.004, 2674377, 18440794.
30. Subbaramaiah K, Howe LR, Port ER, Brogi E, Fishman J, Liu CH, Hla T, Hudis C, Dannenberg AJ. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res 2006, 66:5504-5511. 10.1158/0008-5472.CAN-05-4076, 16707480.
31. Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW, Xu J. Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis. Cancer Res 2005, 65:7993-8002.
32. Kuang SQ, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 2004, 64:1875-1885. 10.1158/0008-5472.CAN-03-3745, 14996752.
33. Torres-Arzayus MI, Font de MJ, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004, 6:263-274. 10.1016/j.ccr.2004.06.027, 15380517.
34. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer. Mol Endocrinol 2012, 26:550-561. 10.1210/me.2011-1101, 22403175.
35. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012, 18:605-611. 10.1038/nm.2661, 22406747.
36. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 2012, 43:1300-1307. Hum Pathol, 2012, 10.1016/j.humpath.2011.10.010, 22245111.
37. Natoli G, Testa G, De Santa F. The future therapeutic potential of histone demethylases: a critical analysis. Curr Opin Drug Discov Dev 2009, 12:607-615.
38. Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, Ju BG, Ohgi KA, Wang J, Escoubet-Lozach L, Rose DW, Glass CK, Fu XD, Rosenfeld MG. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007, 128:505-518. 10.1016/j.cell.2006.12.038, 1994663, 17289570.
39. Forneris F, Binda C, Battaglioli E, Mattevi A. LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem Sci 2008, 33:181-189. 10.1016/j.tibs.2008.01.003, 18343668.
40. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 2009, 69:2065-2071.
41. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye T, Zhang H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011, 71:7238-7249. 10.1158/0008-5472.CAN-11-0896, 21975933.
42. Nair SS, Mishra SK, Yang Z, Balasenthil S, Kumar R, Vadlamudi RK. Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res 2004, 64:6416-6423. 10.1158/0008-5472.CAN-04-1786, 15374949.
43. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935. 10.1093/jnci/djh166, 15199112.
44. Pietras RJ. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 2006, 11:704-717. 10.1634/theoncologist.11-7-704, 16880230.
45. Chakravarty D, Tekmal RR, Vadlamudi RK. PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life 2010, 62:162-169. 2997573, 20014005.
46. Bulun SE, Simpson ER. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 1994, 30:19-29. 10.1007/BF00682738, 7949202.
47. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011, 125:13-22. 10.1016/j.jsbmb.2011.02.001, 3104073, 21335088.
48. Vadlamudi RK, Rajhans R, Chakravarty D, Nair BC, Nair SS, Evans DB, Chen S, Tekmal RR. Regulation of aromatase induction by nuclear receptor coregulator PELP1. J Steroid Biochem Mol Biol 2010, 118:211-218. 10.1016/j.jsbmb.2009.09.009, 2826517, 19800002.